Transplant News and Research

RSS

Angel MedFlight helps liver transplant patient claim insurance for life flight transportation

Last year, Sally (a patient suffering from end stage liver failure) was in need of life flight transportation to be evaluated for a liver transplant. Her doctors told her she needed to receive the evaluation in order to get on the transplant list. Travel by ground ambulance or commercial flight were not an option due to her condition. Her health insurance company told her they would not cover the air ambulance medical transport. But last week, after four appeals and countless hours of work by Angel MedFlight's patient advocates, that decision was reversed.

1 Sep 2009

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).

1 Sep 2009

Race, gender and insurance status influence liver transplant decisions

Patient race, gender and insurance status influence decisions about who will go on to receive liver transplants, according to a University of Pittsburgh School of Medicine study.

1 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

Leading experts in health and health care reform to take part in symposium

With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation’s leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

High dosage of ursodeoxycholic acid does not help PSC patients

A national team of researchers led by scientists at Mayo Clinic has found that a common treatment for primary sclerosing cholangitis, a chronic liver disease, is not helpful for patients, according to a study published this month in the journal Hepatology.

29 Aug 2009

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Geneuity Clinical Research Services announces the recent validation and use in clinical trials of two human biomarker assays that play a key role in the early detection of kidney damage.

29 Aug 2009

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

According to the Centers for Disease Control and Prevention (CDC) 1.5 to 2 million Americans are infected with the hepatitis B virus (HBV). Prior studies have shown there to be significant racial differences in access to and outcomes of liver transplantation. Recently, doctors from across the U.S. conducted a multicenter retrospective-prospective study of the waitlist status and outcomes of liver transplant patients with HBV infection.

28 Aug 2009

80 million American men and women suffer from male or female pattern hair loss according to a study

While lately most people are skeptical about their return on investment from stocks, it appears they have no qualms about making a solid investment in their locks.

27 Aug 2009

Urgent requirement for O negative blood group in Memorial Blood Centers

The need for blood never takes a vacation. Every two seconds, someone in our community needs blood. From premature infants to an organ transplant recipient who will typically require 40 units of blood to survive. And right now, the need is urgent. We are currently facing a shortage of Type 0 negative, the universal blood type that can be given to save the life of anyone, from premature infants and children having heart surgery to an organ transplant recipient who will typically require 40 units of blood to survive. Type B negative blood also is urgently needed.

27 Aug 2009

Studies suggest that venous ischemia causes greater injury than arterial ischemia

The research team led by Professor Guzman-de la Garza of the Autonomous University of Nuevo Leon, Mexico, used a rodent model of intestinal I/R to study the different inflammatory mediators that are associated with venous, arterial or total vascular occlusion.

27 Aug 2009

Research study indicates that liver regeneration could affect the metabolism of tacrolimus in LDLT

Several studies have shown that living donor liver transplant (LDLT) recipients required smaller doses of tacrolimus compared with deceased donor liver transplant (DDLT) patients, which indicated that liver regeneration could affect the metabolism of tacrolimus in LDLT.

27 Aug 2009

MedAssets to deliver transformational revenue cycle solutions for Saint Barnabas Health Care System

MedAssets, Inc. today announced that it has signed a long-term agreement to deliver its transformational revenue cycle solutions to Saint Barnabas Health Care System (SBHCS), the largest integrated health care delivery system in New Jersey. MedAssets will provide revenue cycle process reengineering services, powered by the continued deployment of web-based software and execution of ongoing primary accounts receivable billing and follow-up services.

26 Aug 2009

TBI and NWTS to serve surgeons and hospitals by supplying transplantable tissues

TBI/Tissue Banks International, one of the nation's largest eye and tissue banking networks, and Northwest Tissue Services (NWTS), a Puget Sound Blood Center program, have entered into a partnership that will allow both organizations to more efficiently serve surgeons and hospitals that rely on them for transplantable tissue.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Transplant News and Research

Angel MedFlight helps liver transplant patient claim insurance for life flight transportation

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Race, gender and insurance status influence liver transplant decisions

OHSU study reveals that fluoroquinolones may cause double vision

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Leading experts in health and health care reform to take part in symposium

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

High dosage of ursodeoxycholic acid does not help PSC patients

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

80 million American men and women suffer from male or female pattern hair loss according to a study

Urgent requirement for O negative blood group in Memorial Blood Centers

Studies suggest that venous ischemia causes greater injury than arterial ischemia

Research study indicates that liver regeneration could affect the metabolism of tacrolimus in LDLT

MedAssets to deliver transformational revenue cycle solutions for Saint Barnabas Health Care System

TBI and NWTS to serve surgeons and hospitals by supplying transplantable tissues

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Combined therapy for acute leukemia shows promising results

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News